Description
LINAMET ER 5/1000 is prescribed for the management of type 2 diabetes mellitus in adults, particularly when diet and exercise alone do not provide adequate glycemic control. This extended-release formulation combines Linagliptin, a DPP-4 inhibitor, and Metformin Hydrochloride, a biguanide, to improve blood glucose levels. Linagliptin works by increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner, while Metformin reduces hepatic glucose production and improves insulin sensitivity. The extended-release formulation allows for once-daily dosing, enhancing patient compliance. The recommended starting dose is 5 mg of Linagliptin and 1000 mg of Metformin Hydrochloride taken once daily with a meal. Dosage adjustments should be made based on individual efficacy and tolerability, not exceeding a total daily dose of 5 mg Linagliptin and 2000 mg Metformin Hydrochloride. Patients should be monitored for potential side effects, including gastrointestinal disturbances and, rarely, lactic acidosis. As with all medications, LINAMET ER 5/1000 should be used under the supervision of a healthcare professional.
.jpg)
Change Language